Discovery of Amphipathic Dynorphin A Analogues to Inhibit the Neuroexcitatory Effects of Dynorphin A through Bradykinin Receptors in the Spinal Cord

详细信息    查看全文

• 作者：Yeon Sun Lee ; Dhanasekaran Muthu ; Sara M. Hall ; Cyf Ramos-Colon ; David Rankin ; Jackie Hu ; Alexander J. Sandweiss ; Milena De Felice ; Jennifer Yanhua Xie ; Todd W. Vanderah ; Frank Porreca ; Josephine Lai ; Victor J. Hruby
• 刊名：Journal of the American Chemical Society
• 出版年：2014
• 出版时间：May 7, 2014
• 年：2014
• 卷：136
• 期：18
• 页码：6608-6616
• 全文大小：379K
• 年卷期：v.136,no.18(May 7, 2014)
• ISSN：1520-5126

文摘

We hypothesized that under chronic pain conditions, up-regulated dynorphin A (Dyn A) interacts with bradykinin receptors (BRs) in the spinal cord to promote hyperalgesia through an excitatory effect, which is opposite to the well-known inhibitory effect of opioid receptors. Considering the structural dissimilarity between Dyn A and endogenous BR ligands, bradykinin (BK) and kallidin (KD), this interaction could not be predicted, but it allowed us to discover a potential neuroexcitatory target. Well-known BR ligands, BK, [des-Arg¹⁰, Leu⁹]-kallidin (DALKD), and HOE140 showed different binding profiles at rat brain BRs than that previously reported. These results suggest that neuronal BRs in the rat central nervous system (CNS) may be pharmacologically distinct from those previously defined in non-neuronal tissues. Systematic structure鈥揳ctivity relationship (SAR) study at the rat brain BRs was performed, and as a result, a new key structural feature of Dyn A for BR recognition was identified: amphipathicity. NMR studies of two lead ligands, Dyn A-(4鈥?1) 7 and [des-Arg⁷]-Dyn A-(4鈥?1) 14, which showed the same high binding affinity, confirmed that the Arg residue in position 7, which is known to be crucial for Dyn A鈥檚 biological activity, is not necessary, and that a type I 尾-turn structure at the C-terminal part of both ligands plays an important role in retaining good binding affinities at the BRs. Our lead ligand 14 blocked Dyn A-(2鈥?3) 10-induced hyperalgesic effects and motor impairment in in vivo assays using na茂ve rats. In a model of peripheral neuropathy, intrathecal (i.th.) administration of ligand 14 reversed thermal hyperalgesia and mechanical hypersensitivity in a dose-dependent manner in nerve-injured rats. Thus, ligand 14 may inhibit abnormal pain states by blocking the neuroexcitatory effects of enhanced levels of Dyn A, which are likely to be mediated by BRs in the spinal cord.